Rongwei Ye

Rongwei Ye


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
YLYingying Liu
Yingying Liu
NLNan Li
Nan Li
HAHang An
Hang An
ZLZhiwen Li
Zhiwen Li
LZLe Zhang
Le Zhang
RYRongwei Ye
Rongwei Ye
Studies have shown that maternal blood pressure level is associated with neonatal birthweight, but the results are not exactly consistent. As the most common hypertensive disorders during pregnancy, the mechanism of gestational hypertension and pre‐eclampsia that affect fetal growth remain unclear. Our objective was to examine the association of gestational hypertension and pre‐eclampsia with the risk of low birthweight (LBW) and small‐for‐gestational‐age (SGA). Data were obtained from the China–US Collaborative Project for Neural Tube Defects Prevention, a large population‐based cohort study. We selected participants who were registered in two southern provinces, had exact information on gestational blood pressure and pregnancy outcomes, and were not affected by chronic hypertension. Logistic regression was used to adjust for the effects of the main potential confounders, including age, body mass index, education, occupation, ethnicity, folic acid use, and parity. The overall incidences of LBW and SGA were 2.25% and 5.86%, respectively. The incidences of LBW/SGA were 3.58%/7.58% and 6.02%/10.67% for gestational hypertension and pre‐eclampsia group, relative to 2.11%/5.68% and 2.16%/5.74% for normal group. The adjusted odds ratios associated with gestational hypertension/pre‐eclampsia were 1.77 (95% CI: 1.63, 1.92)/3.01 (95% CI: 2.67, 3.40) for LBW and 1.40 (95% CI: 1.32, 1.48)/2.02 (95% CI: 1.84, 2.22) for SGA, respectively. The early onset of gestational hypertension/pre‐eclampsia appeared to be a relatively more detrimental exposure window for both LBW and SGA. Our results support an association between gestational hypertension or pre‐eclampsia and the increased risk of LBW and SGA.

1 April 2013 in Hypertension
Verified
Journal Article
Closed access
PDF file
ZLZhiwen Li
Zhiwen Li
RYRongwei Ye
Rongwei Ye
LZLe Zhang
Le Zhang
HLHongtian Li
Hongtian Li
JLJianmeng Liu
Jianmeng Liu
ARAiguo Ren
Aiguo Ren
Emerging evidence has suggested that folic acid–containing multivitamins may markedly reduce the risk of gestational hypertension or preeclampsia. We examined whether maternal supplementation with folic acid alone during early pregnancy can prevent the occurrence of gestational hypertension and preeclampsia. The data are from a large population-based cohort study established to evaluate the effectiveness of the campaign to prevent neural tube defects with folic acid supplementation in China. We selected participants who were registered in 2 southern provinces, had exact information on folic acid use, and were not affected by chronic hypertension or diabetes mellitus before 20 weeks gestation. A logistic regression model was used to adjust for the effects of the main potential confounders, including age, body mass index, education, occupation, parity, and multiple births. The study size had 99.9% power (α=0.05) to detect a decrease of 10% over the unexposed rate of 9.4% for gestational hypertension. Among the 193 554 women (47.9% took folic acid, 52.1% did not), the overall incidence of gestational hypertension and preeclampsia was 9.5% and 2.5%, respectively. The incidence of gestational hypertension and preeclampsia was 9.7% and 2.5% for women who took folic acid, and 9.4% and 2.4% for women who did not use it. The adjusted risk ratio associated with folic acid use was 1.08 (95% confidence interval, 1.04–1.11) for gestational hypertension and 1.11 (95% confidence interval, 1.04–1.18) for preeclampsia. Our findings suggest that daily consumption of 400 μg folic acid alone during early pregnancy cannot prevent the occurrence of gestational hypertension and preeclampsia.

13 September 2010 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JZJing Zhao
Jing Zhao
JBJuan Bai
Juan Bai
KSKunling Shen
Kunling Shen
LXLi Xiang
Li Xiang
SHSui Huang
Sui Huang
RYRongwei Ye
Rongwei Ye
Several studies conducted during the 1990s indicated that childhood allergic diseases were increasing worldwide, but more recent investigations in some Western countries have suggested that the trend is stabilizing or may even be reversing. However, few data are available on the current status of allergic disease prevalence in Chinese children. The aim of the present study was to investigate the prevalence rates of asthma, allergic rhinitis, and eczema in children of three major cities of China, to determine the status of allergic diseases among Chinese children generally, and to evaluate the prevalence of allergic diseases in children of different ages.

25 February 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JLJian-Meng Liu
Jian-Meng Liu
ZMZuguo Mei
Zuguo Mei
RYRongwei Ye
Rongwei Ye
MSMary K. Serdula
Mary K. Serdula
ARAiguo Ren
Aiguo Ren
MCMary E. Cogswell
Mary E. Cogswell
About 3 million stillbirths and 3 million early neonatal deaths occurred worldwide in 2004, 98% of which were in less developed countries.1 A high perinatal mortality rate was reported in rural China in 2000.2 Potential preventable causes of stillbirths and early neonatal deaths are maternal anemia and related micronutrient deficiencies.3 Quiz Ref ID Aside from perinatal folic acid supplements to prevent neural tube defects, multiple health organizations recommend pregnant women routinely receive iron–folic acid supplements to prevent anemia.4 Meta-analyses of randomized controlled trials (RCTs) indicate that daily prenatal iron–folic acid supplementation prevents iron deficiency and anemia.5,6 The effect of prenatal iron–folic acid supplementation on perinatal mortality and other maternal and infant outcomes remains unclear, particularly among nonanemic women. Thus, some question the added benefit of prophylactic iron supplementation.7

19 March 2013 in Pediatric Obesity
Verified
Journal Article
Closed access
PDF file
HLH. Li
H. Li
RYRongwei Ye
Rongwei Ye
LPL. Pei
L. Pei
ARAiguo Ren
Aiguo Ren
XZX. Zheng
X. Zheng
JLJian-Meng Liu
Jian-Meng Liu

27 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
HAHang An
Hang An
MJMing Jin
Ming Jin
ZLZhiwen Li
Zhiwen Li
LZLe Zhang
Le Zhang
HLHongtian Li
Hongtian Li
NLNan Li
Nan Li
Objective To investigate the impact of gestational hypertension and pre-eclampsia on preterm birth. Design The data were collected from the China–US Collaborative Project for Neural Tube Defect Prevention; this was a large population-based cohort study. Setting and participants We selected participants registered in two southern provinces, for whom we had exact information on gestational blood pressure and pregnancy outcomes, and who were not affected by chronic hypertension. In total, 200 103 participants were recruited from 1993 to 1995. Outcome measures Preterm birth was defined as a singleton pregnancy and birth before 37 gestational weeks. Results The incidences of gestational hypertension and pre-eclampsia were 5.47% and 5.44%, respectively, for women who gave birth at full term, and 5.63% and 7.33%, respectively, for those who gave birth preterm. After adjusting for potential confounders, the risk ratios (RRs) of preterm birth in women with gestational hypertension and pre-eclampsia were 1.04 (95% CI 0.98 to 1.11) and 1.39 (95% CI 1.25 to 1.55), respectively. The associations were stronger for early-onset (<28 weeks of gestation) gestational hypertension (adjusted RR=2.13, 95% CI 1.71 to 2.65) and pre-eclampsia (adjusted RR=8.47, 95% CI 5.59 to 12.80). Conclusions Pre-eclampsia was associated with a higher risk of preterm birth. The early-onset gestational hypertension and pre-eclampsia were associated with more severe risks than late-onset conditions.